55 completed. 55 Phase 2, 9 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 55 | Completed 55 |
| Phase 1 | 9 | Completed 9 |
| Phase 3 | 3 | Completed 3 |
Follow Uveitis: new trials by email Literature Review of Uveitis trials Research Report on Uveitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dusquetide for the Treatment of Behcet's Disease Dusquetide - Behçet Disease | Phase 2 | Completed | Soligenix | 8 | 2024-11-18 | 2026-08-26 |
| Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome Ustekinumab 90 mg - Behcet's Syndrome, Intestinal Type, Myelodysplastic Syndrome | Phase 2 | Completed | Liu Tian | 8 | 2024-03-24 | 2026-05-13 |
| Oftac Eye Drops (0.05% Tacrolimus Ophthalmic Emulsion) for the Treatment of Active Non-infectious Anterior Uveitis Oftac: 0.05% tacrolimus ophthalmic emulsion - Non-Infectious Anterior Uveitis | Phase 1 / Phase 2 | Completed | BioNanoSim Ltd. | 18 | 2024-03-07 | 2026-10-13 |
| Upadacitinib for Refractory Behcet's Syndrome Upadacitinib 15 MG - Behcet Syndrome | Phase 2 | Completed | Liu Tian | 27 | 2024-01-25 | 2025-12-02 |
| A Phase 2 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Prednisolone acetate - Anterior Uveitis | Phase 2 | Completed | VivaVision Biotech, Inc | 89 | 2023-11-27 | 2025-01-27 |
| A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis Brepocitinib - Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis | Phase 2 | Completed | Priovant Therapeutics, Inc. | 26 | 2022-11-14 | 2025-07-25 |
| A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis Izokibep, Prednisone/Prednisolone - Uveitis | Phase 2 | Completed | ACELYRIN Inc. | 7 | 2022-01-06 | 2024-02-12 |
| Low-dose IL-2 Treatment on Behcet's Disease Low-dose IL-2, Placebo - Behcet's Disease | Phase 2 | Completed | HeJing | 60 | 2021-10-12 | 2024-04-03 |
| The Effectivity of Anti Tuberculosis Therapy in Idiopathic Uveitis with Positive IGRA Anti Tuberculosis Drug, Methylprednisolone - Tuberculous Uveitis | Phase 2 | Completed | Fakultas Kedokteran Universitas Indonesia | 78 | 2021-08-27 | 2025-02-05 |
| Suprachoroidal Triamcinolone Acetonide in Harada's Retinal Detachment Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease - Vogt Koyanagi Harada Disease | Phase 2 / Phase 3 | Completed | Benha University | 6 | 2020-04-01 | 2021-10-07 |
| Abatacept in Patients With Birdshot HLA A29 Uveitis Abatacept 125 MG/ML Prefilled Syringe - Eye Diseases, Uveitis | Phase 2 | Completed | Universitaire Ziekenhuizen KU Leuven | 15 | 2019-04-01 | 2023-12-04 |
| ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study) ACTH gel - Uveitis | Phase 2 | Completed | Quan Dong Nguyen | 28 | 2017-11-10 | 2025-12-17 |
| Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis Anakinra, Tocilizumab, Adalimumab - Uveitis, Biotherapy | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 112 | 2017-06-29 | 2025-09-16 |
| Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease Subcutaneous Ustekinumab - Behçet Disease | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 16 | 2017-06-14 | 2025-09-08 |
| Evaluation of EYS606 in Patients With Non-infectious Posterior, Intermediate or Panuveitis pEYS606 - Non-infectious Uveitis | Phase 1 / Phase 2 | Completed | Eyevensys | 15 | 2017-04-04 | 2022-03-10 |
| Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study) Ustekinumab - Uveitis | Phase 2 | Completed | National Eye Institute (NEI) | 8 | 2017-03-30 | 2021-03-26 |
| 1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement Canakinumab - Behcet Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 8 | 2016-06-23 | 2020-06-11 |
| Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis LME636 60 mg/mL ophthalmic solution, Dexamethasone 0.1% ophthalmic solution, LME636 Vehicle - Acute Anterior Uveitis | Phase 2 | Completed | Alcon Research | 45 | 2015-07-17 | 2018-07-02 |
| A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis NS2, Prednisolone acetate ophthalmic suspension (1%) - Non-infectious Anterior Uveitis | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 45 | 2015-03-01 | 2023-03-27 |
| Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis 8% Dexamethasone Sodium Phosphate - Visulex, 15% Dexamethasone Sodium Phosphate - Visulex, Prednisolone Acetate (1%) Eye Drops - Non-Infectious Anterior Uveitis | Phase 1 / Phase 2 | Completed | Aciont Inc | 44 | 2014-10-01 | 2017-04-27 |
Showing 20 of 55. Sign in to see all of them.
Behcet Syndrome (15) · Uveitis, Anterior (10) · Uveitis, Posterior (9) · Uveitis, Intermediate (8) · Panuveitis (6) · Inflammation (5) · Macular Edema (5) · Arthritis, Juvenile (3) · Retinal Vasculitis (3) · Birdshot Chorioretinopathy (2) · Choroidal Effusions (2) · Diabetes Mellitus, Insulin-Dependent, 10 (2) · Ophthalmia, Sympathetic (2) · Retinal Diseases (2)
Uveal Diseases (55) · Eye Diseases (54) · Panuveitis (28) · Skin and Connective Tissue Diseases (19) · Cardiovascular Diseases (17) · Vascular Diseases (17) · Skin Diseases (16) · Skin Diseases, Vascular (16) · Vasculitis (16) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15) · Genetic Diseases, Inborn (15) · Hereditary Autoinflammatory Diseases (15) · Mouth Diseases (15) · Skin Diseases, Genetic (15)
Daclizumab (5) · Prednisone (3) · prednisolone acetate (3) · Abatacept (2) · Adalimumab (2) · Dexamethasone (2) · Interleukin 1 Receptor Antagonist Protein (2) · Interleukin-2 (2) · Ophthalmic Solutions (2) · Ustekinumab (2) · Adrenal Cortex Hormones (1) · Adrenocorticotropic Hormone (1) · Antitubercular Agents (1) · Colchicine (1) · Cyclophosphamide (1)
National Eye Institute (NEI) (10) · Assistance Publique - Hôpitaux de Paris (5) · Novartis Pharmaceuticals (3) · Allergan (2) · Clearside Biomedical, Inc. (2) · Liu Tian (2) · Oregon Health and Science University (2) · Tehran University of Medical Sciences (2) · ACELYRIN Inc. (1) · Aciont Inc (1) · Alcon Research (1) · Aldeyra Therapeutics, Inc. (1) · Amgen (1) · Benha University (1) · BioNanoSim Ltd. (1)
United States (30) · France (8) · Turkey (Türkiye) (5) · China (4) · Germany (4) · United Kingdom (3) · Czechia (2) · India (2) · Iran (2) · Israel (2) · Spain (2) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1)
Bahar Sadeghi, MD (2) · James T Rosenbaum, MD (2) · Thomas Ciulla, MD (2) · Ahmed Abdelshafy, MD (1) · Ahmet Gul, MD (1) · Arash Tehrani Banihashemi, MD, MPH (1) · Arnd Heiligenhaus, MD (1) · Ayhan Dinc, MD (1) · Brendan Johnson, PhD (1) · C. Stephen Foster, MD (1) · C.Stephen Foster, MD, FACS, FACR (1)
PMID 15079763, PMID 17353400, PMID 19268890, PMID 19597921, PMID 19664754, PMID 19717547, PMID 20212194, PMID 20212197, PMID 20704622, PMID 20926833, PMID 21220619, PMID 21913066, PMID 23411886, PMID 23761087, PMID 25638011, PMID 25875256, PMID 27980877, PMID 28335798, PMID 29275333, PMID 30009894, PMID 30472651, PMID 32377822, PMID 32955967, PMID 34864108, PMID 36585127, PMID 37316690, PMID 38782788, PMID 41018498, PMID 41400947, PMID 41643758
2016 (1), 2018 (1), R44EY014772 (1)